Diabetic macular edema remains an important cause of vision loss among patients with diabetes mellitus. Improved control of blood pressure and blood sugar, as well as photocoagulation, are ...

The U.S. Food and Drug Administration has approved Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular edema.

Diabetic macular edema can result in low vision or vision loss. Early treatment can help preserve vision longer. Diabetic macular edema (DME) is a complication of diabetes. Over time, high blood ...

(RTTNews) - EyePoint Pharmaceuticals, Inc. (EYPT), Wednesday announced positive six-month results from the ongoing Phase 2 VERONA clinical trial, evaluating Duravyu for the treatment of diabetic ...

Genentech unit has received FDA approval for its drug Susvimo 100 mg/mL injection for the treatment of diabetic macular edema, a leading cause of blindness for people with diabetes. Susvimo, also ...

today announced that the first patient has been dosed in the OCU200 Phase 1 clinical trial for diabetic macular edema (DME). “OCU200 has the potential to change the treatment landscape for DME ...

Genentech, a member of the Roche Group (RHHBY), announced that the U.S. Food and Drug Administration has approved Susvimo ...